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Infancy (from birth until 1 year of age) is a time of 
rapid changes in the body of a child. These changes af-
fect pharmacokinetics in many ways. The CHER study1 
showed that early antiretroviral (ARV) treatment re-
duces mortality and disease progression among infants 
acquiring HIV infection before 12 weeks of age. As a 
result the World Health Organization has recently re-
vised treatment initiation recommendations in children 
less than 1 year of age: all infants under 12 months of 
age with confirmed HIV infection should be started on 
ARV therapy, irrespective of clinical or immunological 
stage.2 Dosing in infants is challenging because drug 
concentrations are highly variable, there is frequently 
scant pharmacokinetic information on young children, 
and few suitable drug formulations are available. Fur-
thermore, adherence to treatment is reliant on the 
caregiver rather than the patient. Peri- and postnatal 
HIV transmission are reduced by maternal highly ac-
tive ARV treatment (HAART). However, the benefits and 
risks to breast-fed infants of exposure to maternal ARV 
drugs during lactation are poorly understood.  
In this article we review the pharmacokinetics of ARV 
drugs relevant to South African infants, and highlight 
some of the challenges to delivering ARV treatment in 
safe and effective doses.
Growth and development are accompanied by changes 
that influence drug concentrations. As these develop-
mental changes begin in utero, post-conceptional age 
is a better descriptor of maturation than postnatal age. 
Size and age explain a considerable part of the phar-
macokinetic variability. However, there is a non-linear 
relationship between clearance and size. Consequently, 
simple proportional adjustment of the adult dose based 
on weight leads to underestimation of the mainte-
nance dose required in children. Dose calculation 
methods based on scaling of clearance do not account 
for changes during early infancy in multiple processes 
affecting drug absorption, distribution, metabolism 
and elimination. In recent years there has been a trend 
to provide simplified dosing guidelines using weight 
bands, which provide many practical advantages. Ide-
ally dosing would also account for differences in lean 
body size and maturity within the weight bands. 
Drug absorption is highly variable and difficult to pre-
dict. It is determined by multiple interacting factors 
including enteric pH, gastric motility, intestinal transit 
time, the physico-chemical properties of the drug, in-
testinal metabolic capacity and activity of drug trans-
porters. Gastric pH rapidly declines and then rises again 
during the first few days of life. Acidity then increases 
over several months, reaching adult levels (pH 2 - 3) 
between 2 and 7 years. Frequent feeding with milk or 
formula may influence gastric pH. The absorption of 
atazanavir is reduced at a higher pH and it should be 
taken with food to enhance bio-availability. Although 
by 36 weeks’ gestational age an infant has developed 
intestinal motility patterns similar to those in adults, 
motility is irregular and variable, and the frequency of 
movement is reduced until 6 - 8 months of age. Dietary 
factors affect the rate of gastric emptying: increased 
caloric density feeds with increased concentrations 
of complex fat and sugars delay gastric emptying, so 
formula-fed infants may have shorter intestinal transit 
times than breast-fed infants.3
Body composition changes affect drug distribution. 
Total body water (TBW) comprises approximately 90% 
and 75% of body weight in preterm and term infants, 
respectively. By 1 year of age TBW approaches adult 
proportions of 60%. Extracellular fluid ranges from 
65% in premature to 40% in term infants, while adult 
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values of 20% are reached after a year. Preterm in-
fants have very little body fat (1 - 5%). Term infants 
typically have 12 - 15% body fat. By 12 months body 
fat increases to approximately 30% before declining to 
adult levels of 18%.   
Tissue binding of drugs also affects their distribution. 
Bound drugs are inactive. Free drug concentration (un-
bound drug) gives a better indication of how much 
drug is available for distribution to the site of action. In 
adults, lopinavir is highly bound to plasma proteins (98 
- 99%), mainly α1-acid glycoprotein (AAG), for which 
it has the higher affinity, and albumin. Several other 
protease inhibitors (PIs) are highly bound to plasma 
proteins. Marked changes in plasma protein concentra-
tions and their binding characteristics occur during the 
first 2 weeks after birth. Albumin, which binds acidic 
and neutral drugs, increases by almost 30% in the first 
week. Basic drugs bind to AAG, globulins and lipopro-
teins. Neonates have AAG concentrations one-third 
those of children aged 1 year and older. The lower pH of 
neonatal blood (7.25 - 7.3) results in an increased free 
fraction of some drugs. Moreover, drugs may compete 
with free fatty acids and unconjugated bilirubin for 
binding sites. The increased permeability of the blood-
brain barrier during infancy may have implications for 
those with HIV-related encephalopathy. 
PIs and non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) undergo extensive pre-systemic (in the intes-
tine and liver) and systemic (largely hepatic) metabo-
lism. The cytochrome P450 (CYP) enzymes CYP 3A4 
(PIs and nevirapine) and CYP2B6 (NNRTIs) are impor-
tant isoforms for ARV biotransformation. Unlike most 
nucleoside reverse transcriptase inhibitors (NRTIs), zi-
dovudine and abacavir are extensively metabolised in 
the liver: both drugs by glucuronidation, and abacavir 
by the enzyme alcohol dehydrogenase. Maturation of 
drug metabolising enzymes accounts for age-associ-
ated differences in metabolism. Differential rates of 
maturation are associated with the specific metabolic 
enzymes. Activity of CYP 3A4 in the fetus is 30 - 70% 
of that in adults. CYP activity increases during infancy. 
By 1 year of age the activity of most CYP isoforms ex-
ceeds adult values. The capacity for glucuronidation 
is limited at birth and highly variable. Adult levels of 
activity are achieved between 2 months and 3 years 
of age.
The activity and expression of drug transporters such 
as p-glycoprotein are important determinants of drug 
absorption, distribution and clearance. Very little is 
known about the developmental pattern of these 
transporters which, like those of the drug metabolis-
ing enzymes, may be influenced by exogenous factors 
such as diet in addition to genetic and maturational 
determinants. 
NRTIs other than zidovudine and abacavir are eliminat-
ed primarily unchanged by the kidneys. Both glomer-
ular filtration and tubular secretion are immature at 
birth. Before 34 weeks’ gestation the glomerular filtra-
tion rate (GFR) is reduced and highly variable. There-
after, there is a strong correlation between GFR and 
age. Term infants have a GFR of 2 - 4 ml/min, which 
increases to 8 - 20 ml/min during the first few days of 
life. In contrast, premature infants may be born with a 
GFR of 0.6 - 0.8 ml/min, which may increase to 2 - 4 
ml/min during the first few days after birth. By 3 - 6 
months of age adult maturity in GFR is attained.3
There are frequently inadequate pharmacokinetic data 
on infants. Moreover, studies in infants are often lim-
ited by small sample size and sparse sampling. Table I 
sets out pharmacokinetic data for ARV drugs used in 
South African infants.
Dosing of infants is challenging. They cannot swallow 
solid dosing forms. Liquid formulations often have de-
creased stability and require refrigeration. Stavudine, 
for example, comes in a powder that needs reconstitu-
tion before dispensing as an oral solution. It is stable 
for only 30 days in a refrigerator. Lopinavir/ritonavir 
solution may be stored at room temperature (up to 
25°C) if it is used within 42 days. In many high-bur-
den settings access to refrigeration is limited. Stability 
issues therefore complicate drug supply, storage and 
dispensing. Most tablets and capsules should not be 
crushed, as stability and absorption may be altered and 
accurate dosing is impossible. Dispensing and dosing 
errors are common, as the dose has to be translated 
into the volume dispensed or administered. Accurate 
measurement of the dose is challenging for many car-
ers, and liquid formulations need to be shaken well be-
fore administration to ensure that the correct dose is 
administered. Relatively large-volume liquid doses can 
be problematic: infants do not always swallow the en-
tire dose and often spit some of it out. Paediatric for-
mulations such as dispersible fixed-dose combination 
tablets in doses suitable for infants and young children 
may provide considerable advantages. 
The routine use of therapeutic drug monitoring (TDM) 
has not been proven to alter treatment outcomes in 
adults. However, it is recommended that TDM be con-
sidered in paediatric patients (particularly infants and 
severely ill children) owing to unpredictable drug ex-
posure and, in many instances, a paucity of evidence 
to support the dosing guidelines. Additional indications 
include potentially significant drug-drug (see ‘Impact 
of antituberculosis treatment’, below) or drug-food in-
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impairment; treatment-experienced patients who may have viral 
isolates with reduced susceptibility to highly active ARV therapy 
(HAART); use of alternative dosing regimens the safety and efficacy 
of which have not been established in clinical trials; concentra-
tion-dependent toxicity; unexpectedly poor virological response in 
a treatment-naïve person; and monitoring of adherence.25 
The minimum (predose trough) drug concentration is used to moni-
tor virological efficacy. Peak concentrations relate more closely to 
toxicity for some drugs, and the area under the drug concentration-
time curve is a measure of overall systemic exposure. Therapeutic 
ranges have not been defined for NRTIs, which are metabolised 
intracellularly to the active triphosphate, as plasma concentrations 
are not closely related to efficacy.
Target concentrations for NNRTIs and PIs (Table I) are based largely 
on studies in adults. While it is likely that good responses to treat-
ment will be achieved in children, provided that they are given 
drug formulations and doses that achieve drug exposure similar to 
those that have demonstrated safety and efficacy among adults, 
important differences may apply. Routinely, total plasma ARV con-
centrations are measured in the laboratory. The recommended drug 
concentration ranges are therefore based on the sum of the free 
active component and protein-bound drug. Altered protein binding 
during early infancy may alter the proportion of active drug in the 
measured concentration. Furthermore, day-to-day variability com-
plicates interpretation of a single drug concentration result. Drug 
concentration results should be interpreted on an individual basis, 
and safety and efficacy should also be carefully monitored. Clearly, 
poor adherence to treatment needs to be ruled out as a cause of 
low drug concentrations before dose adjustments are made. 
Modern technologies such as liquid chromatography mass spec-
trometry allow drug concentration measurement in low-volume 
samples, thus facilitating TDM in infants. The development of 
methods using blood spots dried onto filter paper is likely to make 
TDM increasingly accessible and affordable. However, although it 
is frequently indicated in infants as part of an integrated approach, 
TDM of ARVs is currently not available to the vast majority patients 
in high-burden settings. 
Although the use of ARV therapy complicates the management of tu-
berculosis, patients with tuberculosis who meet the criteria for ARV 
therapy should be started on an effective ARV regimen once they are 
established on rifampicin-based antituberculosis treatment.
 
Through activation of the pregnane X receptor, which results in 
increased expression of multiple drug metabolising enzymes and 
transporters, rifampicin increases the oral clearance of many 
medications. Rifampicin lowers the concentrations of PIs to sub-
therapeutic levels; nevirapine trough concentrations are reduced 
by about 30% in South African adults;26 and zidovudine concentra-
tions are reported to decline by 50%. There are concerns associated 
with all the currently available co-treatment options for infants, 
and there are very few data on which to base optimal co-treatment 
approaches. Careful monitoring is indicated. 
IMPACT OF ANTITUBERCULOSIS TREATMENT
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In HIV-infected infants exposed to single-dose nevirap-
ine, or maternal NNRTI-containing ARV treatment or 
prevention regimens, PI-based HAART should be start-
ed. Super-boosted lopinavir (extra ritonavir is added to 
lopinavir/ritonavir; a total 12-hourly lopinavir/ritonavir 
dose of 230/230 mg/m2) achieves adequate lopinavir 
exposure in most children older than 6 months dur-
ing rifampicin-containing antituberculosis treatment.27 
However, lopinavir concentrations are highly variable, 
there are no data to support this approach in young-
er infants, and it is poorly tolerated and complex to 
prescribe, dispense and administer. Double-dose lopi-
navir/ritonavir has been shown to result in sub-thera-
peutic concentrations in children during antitubercu-
losis treatment. When adjusted doses of PIs are used 
with rifampicin, TDM should be implemented if it is 
available, and it is essential to regularly monitor liver 
function. Rifabutin (in reduced doses) is preferred to 
rifampicin in adults requiring PIs, but it is expensive 
and suitable formulations are not available for infants 
and young children. 
In many settings nevirapine plus 2 NRTIs is the only 
effective treatment option available to young chil-
dren. Standard doses of nevirapine twice daily provide 
acceptable outcomes in adults with tuberculosis (al-
though it is inferior to efavirenz). Recent evidence sug-
gests, however, that the majority of young children on 
tuberculosis treatment fail to achieve trough concen-
trations >3 mg/l (the lower limit of the recommended 
range),28 and data for infants younger than 6 months 
are lacking. The approach should be used with caution 
until more safety and efficacy information is available, 
and patients should be carefully monitored.
ARV regimens comprising 3 or 4 nucleos(t)ides have 
inferior efficacy compared with PI- and NNRTI-based 
regimens, and are not adequately evaluated in children. 
However, they may have a role in ARV-naïve patients 
with HIV-associated tuberculosis, as the substantial 
interactions of rifampicin with the PIs and NNRTIs are 
avoided. 
The use of ARV drugs by mothers is increasing as ac-
cess to treatment programmes improves, thresholds for 
starting treatment become less stringent and ARVs are 
implemented to prevent HIV transmission during child-
birth and breastfeeding. However, the benefits and risks 
to breastfed infants of exposure to maternal ARV drugs 
during lactation are poorly understood. The different 
physicochemical properties of drugs lead to differential 
transfer from maternal plasma to breastmilk (Table II) 
and to the breastfed infant. Incomplete exposure of in-
fants to components of a maternal regimen may favour 
the selection of drug-resistant virus should transmis-
sion occur. Little is known about the safety of ARVs in 
breastmilk. The small doses of NRTIs and PIs ingested 
through breastmilk may invoke subtle or idiosyncratic 
side-effects, while the more substantial exposure to 
nevirapine and efavirenz are of more importance. 
A study of ARV concentrations in exclusively breastfed 
Kenyan infants  younger than 6 months, whose moth-
ers were receiving HAART, found biologically signifi-
cant concentrations of lamivudine and nevirapine, but 
not zidovudine.29 Lamivudine concentrations were just 
greater than the 50% inhibitory concentration (IC50) for 
wild-type HIV. Median nevirapine concentrations (0.90 
mg/l) were well above the median HIV IC50 (0.017 mg/
l).29 Rwandan infants of mothers receiving efavirenz-
based HAART achieved median efavirenz concentra-
tions of 0.87 mg/l through breastmilk ingestion, just 
below the recommended target trough concentration 
of >1 mg/l.30 Transfer of NNRTIs from mothers receiving 
HAART may therefore result in substantial exposure in 
their breastfed infants along with potential benefit for 
prevention of HIV transmission, the risk of side-effects 
and the risk of developing viral resistance to NNRTIs 
	 Median	breastmilk/maternal	 Estimated	median	daily		 Median	infant	
Drug	 plasma	ratio	(IQR)		 infant	dose	from	breastmilk	 concentration		 Reference
Zidovudine 0.44 (0.23, 0.65) 1.35 µg/kg/d (<1 000 × lower  Undetectable* 29 
  than standard infant dose for  
  PMTCT)
Lamivudine 2.56 (1.79, 3.89) 182 µg/kg (2% daily treatment dose for  0.02 - 0.03 mg/l* 29 
  >3-month-olds)
Nevirapine 0.75 (0.64, 0.89) 600 µg/kg/d 0.73 - 1.03 mg/l*  29
  (15% of the 4 mg/kg/d infant dose being  
  evaluated in PMTCT studies)
Efavirenz 0.52  (0.43, 0.62) - 0.87 mg/l† 30
Lopinavir 0.11 (0.06, 0.15) - Undetectable† 31
Ritonavir 0.11 (0.08, 0.18) - Undetectable† 31
*Whole blood concentrations from 2 to 14 weeks after birth. 
†Plasma concentrations 6 weeks to 6 months after birth. 
IQR = intraquartile range; PMTCT = prevention of mother-to-child transmission. 
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should HIV transmission occur. Conversely, breastmilk 
concentrations of PIs are low and there is little if any 
transfer to the infant via breastmilk.31
The pharmacokinetics of infancy are unique and evolve 
rapidly during this period of life. Drug doses used dur-
ing infancy are often based on extrapolation from 
other age groups. For many of the ARV drugs, evidence 
to support the dosing approaches is rudimentary and 
suitable dosage forms are lacking. It is important to 
ensure that adequate concentrations of ARV drugs 
are obtained, to ensure efficacy and prevent toxicity. 
The infant is further exposed to maternal ARV drugs 
before and during birth, and during lactation. There 
is an urgent need for pharmacokinetic studies in the 
relevant infant populations to support optimal dosing 
approaches which should then undergo more extensive 
evaluation of efficacy and safety. As drug concentra-
tions in infants are highly unpredictable, particularly in 
neonates and premature infants, severely ill children or 
those treated concomitantly with interacting medica-
tions, TDM has a role in optimising individual dosing. 
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